Michler, T. et al. The lack of HBsAg secretion does neither facilitate induction of antiviral T cell responses nor Hepatitis B Virus clearance in mice. Antiviral Res. 226:105896 (2024)
Xie, Z. & Protzer, U. Activating adaptive immunity by bispecific, T-cell engager antibodies bridging infected and immune-effector cells is a promising novel therapy for chronic hepatitis B. Antiviral Res. 229:105972 (2024)
Ko, C. et al. Intramolecular recombination enables the formation of hepatitis B virus (HBV) cccDNA in mice after HBV genome transfer using recombinant AAV vectors. Antiviral Res. 194, 05140:105140 (2021)
Svilenov, H.L.* et al. Picomolar inhibition of SARS-CoV-2 variants of concern by an engineered ACE2-IgG4-Fc fusion protein. Antiviral Res. 196:105197 (2021)
Tan, A.T.* & Schreiber, S. Adoptive T-cell therapy for HBV-associated HCC and HBV infection. Antiviral Res. 176:104748 (2020)
Xia, Y. et al. PASylated interferon α efficiently suppresses hepatitis B virus and induces anti-HBs seroconversion in HBV-transgenic mice. Antiviral Res. 161, 134-143 (2019)
Esser, K. et al. Lipase inhibitor orlistat prevents hepatitis B virus infection by targeting an early step in the virus life cycle. Antiviral Res. 151, 4-7 (2018)
Golsaz-Shirazi, F.* et al. Construction of a hepatitis B virus neutralizing chimeric monoclonal antibody recognizing escape mutants of the viral surface antigen (HBsAg). Antiviral Res. 144, 153-163 (2017)
Yin, R.* et al. A Raf kinase inhibitor demonstrates antiviral activities both in vitro and in vivo against different genotypes of virulent Newcastle disease virus. Antiviral Res. 133, 140-144 (2016)
Zhang, E.* ; Kosinska, A. ; Lu, M.* ; Yan, H.* & Roggendorf, M. Current status of immunomodulatory therapy in chronic hepatitis B, fifty years after discovery of the virus: Search for the "magic bullet" to kill cccDNA. Antiviral Res. 123, 193-203 (2015)
Lucifora, J. ; Esser, K. & Protzer, U. Ezetimibe blocks hepatitis B virus infection after virus uptake into hepatocytes. Antiviral Res. 97, 195-197 (2013)